Imugene Ltd, a pharmaceutical company based in Australia, is a high-risk clinical-stage immuno-oncology company focused on developing innovative cancer vaccines and therapeutics. With a Risk Rating Score of 30.7, Imugene Ltd specializes in products like HER-Vaxx, PD1-Vaxx, CF33, and CF33 CD19, with HER-Vaxx being a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company's main focus is on Research and Development of oncolytic immunotherapies. Experience cutting-edge ESG technologies in pharmaceuticals with Imugene Ltd.